Company news
Terns Pharmaceuticals, Inc. news in 2022
Terns Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
Terns Announces Closing of Public Offering of Shares of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 22, 2022
Terns Announces Pricing of $75 Million Public Offering
December 19, 2022
Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit
November 30, 2022
Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 8, 2022
Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022
November 3, 2022
Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022
October 25, 2022
Terns Pharmaceuticals to Present at the H. C. Wainwright 6th Annual NASH Investor Conference
October 10, 2022
Terns Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 6, 2022
Terns Announces $65 Million Oversubscribed Offering
August 11, 2022
Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights
August 7, 2022
Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors
July 26, 2022
Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress™ 2022
June 21, 2022
Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022
June 7, 2022
Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer
May 31, 2022
Terns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates
May 15, 2022
Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
April 3, 2022
Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201
March 20, 2022
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
March 2, 2022
Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference
February 27, 2022
Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer
January 5, 2022
Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference
January 2, 2022